age
float64 18
102
| sex
stringclasses 2
values | hospdead
int64 0
1
| slos
int64 3
343
| dzgroup
stringclasses 8
values | dzclass
stringclasses 4
values | num.co
int64 0
9
| edu
float64 0
31
⌀ | income
stringclasses 4
values | scoma
float64 0
100
⌀ | charges
float64 1.17k
1.44M
⌀ | totcst
float64 0
633k
⌀ | totmcst
float64 -102.72
711k
⌀ | avtisst
float64 1
83
⌀ | race
stringclasses 5
values | sps
float64 0.2
99.2
⌀ | aps
float64 0
143
⌀ | surv2m
float64 0
0.97
⌀ | surv6m
float64 0
0.95
⌀ | hday
int64 1
148
| diabetes
int64 0
1
| dementia
int64 0
1
| ca
stringclasses 3
values | prg2m
float64 0
1
⌀ | prg6m
float64 0
1
⌀ | dnr
stringclasses 3
values | dnrday
float64 -88
285
⌀ | meanbp
float64 0
195
⌀ | wblc
float64 0
200
⌀ | hrt
float64 0
300
⌀ | resp
float64 0
90
⌀ | temp
float64 31.7
41.7
⌀ | pafi
float64 12
890
⌀ | alb
float64 0.4
29
⌀ | bili
float64 0.1
63
⌀ | crea
float64 0.1
21.5
⌀ | sod
float64 110
181
⌀ | ph
float64 6.83
7.77
⌀ | glucose
float64 0
1.09k
⌀ | bun
float64 1
300
⌀ | urine
float64 0
9k
⌀ | adlp
float64 0
7
⌀ | adls
float64 0
7
⌀ | sfdm2
stringclasses 5
values | adlsc
float64 0
7.07
| event_times
int64 3
2.03k
| event_indicators
int64 0
1
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
62.26398
|
male
| 0
| 8
|
CHF
|
COPD/CHF/Cirrhosis
| 3
| 12
|
$11-$25k
| 0
| 26,205
| null | null | 29
|
black
| 37.195313
| 65
| 0.567993
| 0.372986
| 1
| 1
| 0
|
no
| 0.8
| 0.6
|
no dnr
| 8
| 74
| 2.099609
| 132
| 36
| 38.79688
| 419
| null | 5.699219
| 0.699951
| 135
| 7.379883
| 77
| 14
| 1,750
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 450
| 0
|
76.82996
|
male
| 0
| 25
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 17
|
$25-$50k
| 9
| 120,051
| null | null | 24.5
|
white
| 21
| 34
| 0.642944
| 0.541992
| 33
| 0
| 0
|
yes
| 0.75
| 0.5
|
no dnr
| 25
| 130
| 15.099609
| 115
| 40
| 35
| 185.6875
| 2.899902
| 0.699951
| 1.099854
| 139
| 7.5
| 116
| 14
| null | null | 0
|
adl>=4 (>=5 if sur)
| 0
| 449
| 0
|
45.27899
|
male
| 1
| 7
|
Cirrhosis
|
COPD/CHF/Cirrhosis
| 5
| 12
|
under $11k
| 9
| 21,231
| null | null | 20.5
|
black
| 32.398438
| 55
| 0.600952
| 0.411987
| 2
| 0
| 0
|
no
| 0.4
| 0.88
|
dnr after sadm
| 6
| 72
| 9.898438
| 83
| 20
| 36.39844
| 319
| null | null | 0.799927
| 135
| 7.479492
| 102
| 18
| 500
| null | 6
|
<2 mo. follow-up
| 6
| 7
| 1
|
54.793
|
female
| 0
| 8
|
COPD
|
COPD/CHF/Cirrhosis
| 3
| 10
|
$25-$50k
| 0
| 11,367
| null | null | 9
|
white
| 20.398438
| 35
| 0.899902
| 0.831909
| 1
| 0
| 0
|
no
| 0.9
| 0.9
|
no dnr
| 8
| 71
| 6.899414
| 100
| 18
| 36.5
| 361.875
| null | 0.699951
| 0.799927
| 138
| 7.439453
| 86
| 8
| 2,400
| null | null |
SIP>=30
| 3.366699
| 449
| 0
|
58.61697
|
male
| 1
| 13
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 0
|
under $11k
| 0
| 39,128
| null | null | 22
|
white
| 24
| 34
| 0.779907
| 0.707886
| 9
| 0
| 0
|
no
| 0.8
| 0.3
|
dnr after sadm
| 4
| 53
| 6.799805
| 108
| 20
| 38
| null | null | 8.199219
| 0.699951
| 130
| null | 80
| 9
| 1,185
| null | 0
|
<2 mo. follow-up
| 0
| 13
| 1
|
46.26398
|
male
| 1
| 15
|
MOSF w/Malig
|
ARF/MOSF
| 1
| 12
|
under $11k
| 0
| 80,718
| null | null | 36.666657
|
other
| 38.796875
| 63
| 0.208984
| 0.113998
| 3
| 0
| 0
|
metastatic
| 0.6
| 0.6
|
dnr after sadm
| 11
| 73
| 7.799805
| 76
| 24
| 36.89844
| 242.84375
| 3
| 0.599976
| 0.699951
| 139
| 7.369141
| 227
| 14
| null | null | 0
|
<2 mo. follow-up
| 0
| 15
| 1
|
72.88696
|
male
| 1
| 10
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| null | null | 0
| 122,871
| null | null | 50
|
white
| 51.695313
| 78
| 0.042
| 0.011999
| 11
| 0
| 0
|
no
| 0.2
| 0.1
|
dnr after sadm
| 10
| 138
| 14
| 105
| 29
| 38.69531
| 380
| 2.099609
| 0.199982
| 1.899902
| 155
| 7.469727
| 621
| 43
| 3,135
| null | null |
<2 mo. follow-up
| 1.925293
| 10
| 1
|
57.659
|
female
| 1
| 31
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| null | null | 0
| 191,281
| null | null | 48.25
|
white
| 20.199219
| 26
| 0.842896
| 0.78894
| 6
| 1
| 0
|
no
| 0.96
| 0.94
|
dnr after sadm
| 12
| 65
| 6.899414
| 115
| 30
| 35
| 231.65625
| 3.399902
| null | 0.799927
| 131
| 7.439453
| 142
| 30
| 2,375
| null | 0
|
<2 mo. follow-up
| 0
| 31
| 1
|
66.72095
|
female
| 1
| 38
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 4
|
$11-$25k
| 44
| null | null | null | 35.25
|
black
| 25.5
| 73
| 0.554932
| 0.441956
| 6
| 0
| 0
|
no
| 0.05
| 0.01
| null | null | 81
| 6.199219
| 72
| 20
| 37.79688
| null | 2.699707
| 3.399902
| 1.199951
| 130
| null | 104
| 15
| null | null | 0
|
<2 mo. follow-up
| 0
| 38
| 1
|
77.65094
|
male
| 0
| 25
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 8
| null | 0
| 90,077
| null | null | 28
|
white
| 29.898438
| 70
| 0.643921
| 0.543945
| 1
| 0
| 0
|
no
| 0.3
| 0.2
|
dnr after sadm
| 2
| 63
| 11.699219
| 110
| 44
| 37.69531
| 114.28125
| 3.799805
| 0.899902
| 0.699951
| 138
| 7.469727
| 129
| 32
| 2,125
| null | 0
|
no(M2 and SIP pres)
| 0
| 447
| 0
|
70.15997
|
male
| 0
| 23
|
Coma
|
Coma
| 0
| null |
under $11k
| 0
| 62,877
| null | null | 29.333328
|
black
| 16.597656
| 31
| 0.787964
| 0.746948
| 1
| 0
| 0
|
no
| 0.5
| 0.45
|
no dnr
| 23
| 52
| 20.796875
| 135
| 22
| 37.69531
| 110.90625
| null | 6.399414
| 2.799805
| 132
| 7.379883
| 50
| 96
| 126
| null | 0
|
adl>=4 (>=5 if sur)
| 0
| 446
| 0
|
37.51099
|
male
| 0
| 18
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| null | null | 37
| 71,649
| null | null | 33.666657
|
white
| 26.097656
| 45
| 0.747925
| 0.668945
| 3
| 0
| 0
|
no
| null | null |
no dnr
| 18
| 105
| 8.798828
| 160
| 14
| 36.5
| 271.375
| 2.899902
| 0.5
| 0.599976
| 138
| 7.519531
| 171
| 14
| 930
| null | null | null | 2.772949
| 446
| 0
|
44.60199
|
male
| 0
| 6
|
Cirrhosis
|
COPD/CHF/Cirrhosis
| 4
| 10
|
under $11k
| 0
| 17,393
| null | null | 14
|
white
| 20.296875
| 35
| 0.859985
| 0.767944
| 1
| 0
| 0
|
no
| 0.75
| 0.65
|
no dnr
| 6
| 123
| 11.398438
| 125
| 20
| 36.89844
| 144.4375
| 2.399902
| 1.699951
| 2.399902
| 146
| 7.469727
| 240
| 28
| 3,670
| 6
| 5
|
<2 mo. follow-up
| 5
| 15
| 1
|
61.73297
|
female
| 0
| 11
|
CHF
|
COPD/CHF/Cirrhosis
| 2
| 9
| null | 9
| 39,205
| null | null | 34.5
|
other
| 37.898438
| 48
| 0.510986
| 0.309998
| 1
| 1
| 0
|
no
| 0.35
| 0.3
|
dnr after sadm
| 1
| 68
| 5.699219
| 74
| 28
| 36.29688
| null | null | null | 1.899902
| 138
| null | 79
| 41
| 1,000
| null | 0
|
no(M2 and SIP pres)
| 0
| 446
| 0
|
39.67697
|
male
| 0
| 11
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 14
|
$25-$50k
| 44
| 35,968
| null | null | 29
|
black
| 26.699219
| 41
| 0.735962
| 0.652954
| 1
| 0
| 0
|
no
| 0.85
| 0.84
|
no dnr
| 11
| 79
| 5.5
| 80
| 20
| 36.59375
| null | 3.699707
| null | 0.799927
| 145
| null | 98
| 11
| 975
| null | 0
|
no(M2 and SIP pres)
| 0
| 446
| 0
|
75.30499
|
female
| 1
| 11
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 3
| 8
|
under $11k
| 0
| 139,100
| null | null | 37
|
black
| 30.398438
| 63
| 0.45697
| 0.337952
| 17
| 0
| 0
|
yes
| 0.6
| 0.5
|
dnr after sadm
| 8
| 73
| 10.199219
| 76
| 24
| 38.69531
| null | 3.599609
| 0.299988
| 0.599976
| 134
| null | 85
| 8
| 3,100
| null | 5
|
<2 mo. follow-up
| 5
| 11
| 1
|
54.20898
|
male
| 0
| 9
|
CHF
|
COPD/CHF/Cirrhosis
| 3
| 16
|
$11-$25k
| 0
| 7,800
| null | null | 13
|
white
| 25.597656
| 41
| 0.830933
| 0.723999
| 1
| 1
| 0
|
no
| 0.8
| 0.7
|
no dnr
| 9
| 84
| 10.099609
| 76
| 22
| 35.29688
| 404.75
| 3.199707
| 1
| 1.5
| 134
| 7.489258
| 107
| 88
| 950
| 0
| 5
|
no(M2 and SIP pres)
| 5
| 445
| 0
|
41.87799
|
male
| 0
| 4
|
Lung Cancer
|
Cancer
| 1
| 14
|
$25-$50k
| 0
| 10,471
| null | null | 12
|
white
| 12
| 12
| 0.831909
| 0.633911
| 1
| 0
| 0
|
metastatic
| 0.9
| 0.7
|
no dnr
| 4
| 108
| 5.799805
| 125
| 6
| 36.39844
| 197.5
| 2.399902
| 7.299805
| 1.099854
| 145
| 7.359375
| 103
| 14
| 2,070
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 389
| 1
|
44.10098
|
male
| 0
| 5
|
Lung Cancer
|
Cancer
| 1
| 12
|
under $11k
| 9
| 14,569
| null | null | 15
|
white
| 7.699219
| 12
| 0.859985
| 0.68689
| 1
| 0
| 0
|
metastatic
| null | null |
no dnr
| 5
| 28
| 41.09375
| 0
| 0
| 36.59375
| 88.5625
| null | null | 1.599854
| 149
| 7.379883
| 163
| 53
| 110
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 196
| 1
|
56.50897
|
male
| 1
| 14
|
CHF
|
COPD/CHF/Cirrhosis
| 2
| 8
|
$11-$25k
| 0
| 34,959
| null | null | 19.333328
|
other
| 24.5
| 26
| 0.836914
| 0.73291
| 1
| 0
| 0
|
no
| 0.8
| 0.7
|
dnr after sadm
| 6
| 105
| 17.199219
| 125
| 24
| 39.5
| 266.625
| null | 0.599976
| 0.699951
| 131
| 7.489258
| 87
| 6
| 1,375
| null | 3
|
<2 mo. follow-up
| 3
| 14
| 1
|
81.85596
|
male
| 0
| 8
|
CHF
|
COPD/CHF/Cirrhosis
| 2
| 10
|
under $11k
| 0
| 5,708
| null | null | 8
|
white
| 20.199219
| 34
| 0.802979
| 0.681885
| 1
| 0
| 0
|
no
| 0.8
| 0.65
|
no dnr
| 8
| 165
| 10.199219
| 105
| 12
| 38.09375
| 147.5
| 2.299805
| 0.599976
| 0.899902
| 145
| 7.359375
| 160
| 21
| 4,500
| null | 0
|
no(M2 and SIP pres)
| 0
| 444
| 0
|
59.67999
|
male
| 0
| 18
|
Colon Cancer
|
Cancer
| 1
| 12
|
>$50k
| 0
| 23,874
| null | null | 9.666664
|
white
| 9
| 9
| 0.904907
| 0.780884
| 1
| 0
| 0
|
metastatic
| 0.8
| 0.5
|
no dnr
| 18
| 62
| 9.699219
| 75
| 32
| 36.19531
| 179.5625
| 3.199707
| 4
| 2
| 139
| 7.419922
| 137
| 47
| 88.1875
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 146
| 1
|
51.504
|
female
| 1
| 20
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 3
| 16
|
$25-$50k
| 9
| 96,981
| null | null | 25
|
black
| 22.5
| 33
| 0.797974
| 0.731934
| 13
| 1
| 0
|
no
| 0.5
| 0.5
|
dnr after sadm
| 17
| 78
| 22.5
| 70
| 32
| 35.09375
| 190
| 2.899902
| 0.399963
| 0.799927
| 138
| 7.359375
| 208
| 12
| 1,920
| null | 0
|
<2 mo. follow-up
| 0
| 20
| 1
|
19.81899
|
male
| 0
| 18
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 13
|
$25-$50k
| 0
| 37,577
| null | null | 23.666656
|
white
| 21.597656
| 35
| 0.928955
| 0.902954
| 1
| 0
| 0
|
no
| 0.9
| 0.9
|
no dnr
| 18
| 125
| 9.898438
| 125
| 11
| 39.19531
| 330
| null | null | 0.5
| 135
| 7.40918
| 184
| 7
| 1,865
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 442
| 0
|
38.35699
|
male
| 0
| 14
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 15
| null | 0
| 28,330
| null | null | 14.333328
|
black
| 29.699219
| 46
| 0.802979
| 0.737915
| 2
| 0
| 0
|
no
| 0.8
| 0.8
|
no dnr
| 14
| 108
| 24.296875
| 75
| 12
| 38
| 230
| 1.799805
| null | 7.5
| 130
| 7.439453
| 330
| 73
| 90
| 0
| 0
| null | 0
| 442
| 0
|
81.24799
|
male
| 0
| 16
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 5
|
$11-$25k
| 0
| 35,584
| null | null | 20
|
white
| 26.796875
| 51
| 0.586914
| 0.47699
| 3
| 0
| 0
|
yes
| 0.25
| 0.05
|
dnr after sadm
| 12
| 73
| 8.298828
| 100
| 22
| 36.5
| null | null | null | 2
| 133
| null | 88
| 34
| null | null | 6
|
adl>=4 (>=5 if sur)
| 6
| 91
| 1
|
81.45898
|
male
| 0
| 19
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 7
|
under $11k
| 0
| 148,940
| null | null | 24.666656
|
white
| 23.898438
| 23
| 0.656982
| 0.557983
| 27
| 0
| 0
|
no
| 0.25
| 0.15
|
dnr after sadm
| 2
| 68
| 12.699219
| 82
| 20
| 36.29688
| null | 3.599609
| 0.599976
| 0.699951
| 151
| null | 89
| 12
| 1,000
| null | 7
|
adl>=4 (>=5 if sur)
| 7
| 349
| 1
|
49.52197
|
male
| 0
| 6
|
Lung Cancer
|
Cancer
| 1
| 12
|
>$50k
| 0
| 10,604
| null | null | 20
|
white
| 28
| 22
| 0.484985
| 0.165985
| 1
| 0
| 0
|
metastatic
| 0.9
| 0.6
|
dnr after sadm
| 4
| 112
| 9.199219
| 105
| 41
| 37.79688
| 161.21875
| null | null | 0.899902
| 140
| 7.449219
| 135
| 13
| 2,850
| 0
| 0
|
<2 mo. follow-up
| 0
| 53
| 1
|
19.127
|
female
| 0
| 4
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 12
| null | 0
| 17,649
| null | null | 18
|
white
| 23
| 19
| 0.921997
| 0.893921
| 1
| 0
| 0
|
no
| 0.95
| 0.95
|
no dnr
| 4
| 104
| 8.699219
| 112
| 20
| 37.5
| null | 3.099609
| 0.599976
| 0.899902
| 135
| null | 314
| 11
| 5,700
| null | 0
|
no(M2 and SIP pres)
| 0
| 439
| 0
|
79.41998
|
male
| 1
| 52
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 3
| 13
| null | 9
| 134,458
| null | null | 31.75
|
white
| 19
| 38
| 0.806885
| 0.74292
| 1
| 0
| 0
|
no
| 0.7
| 0.65
|
dnr after sadm
| 48
| 107
| 11.599609
| 50
| 22
| 36.69531
| 155
| null | null | 0.899902
| 135
| 7.469727
| 103
| 23
| 2,625
| null | 6
|
<2 mo. follow-up
| 6
| 52
| 1
|
36.06799
|
male
| 0
| 32
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 3
| 7
|
under $11k
| 0
| 73,203
| null | null | 19
|
black
| 20.398438
| 35
| 0.889893
| 0.850952
| 7
| 1
| 0
|
no
| null | null |
no dnr
| 32
| 52
| 36.898438
| 145
| 10
| 39.09375
| 167.5
| null | null | 1.5
| 139
| 7.399414
| 145
| 17
| 1,650
| 2
| 1
|
SIP>=30
| 1
| 142
| 1
|
69.66699
|
female
| 0
| 15
|
Colon Cancer
|
Cancer
| 1
| 11
|
$25-$50k
| 0
| 25,405
| null | null | 14.333328
|
white
| 13.798828
| 19
| 0.8479
| 0.664917
| 1
| 0
| 0
|
metastatic
| 0.9
| 0.75
|
no dnr
| 15
| 78
| 10.199219
| 65
| 16
| 36.19531
| 642.75
| null | 1.699951
| 1.099854
| 140
| 7.349609
| 158
| 10
| 2,950
| null | 1
| null | 1
| 326
| 1
|
34.42297
|
male
| 0
| 4
|
Cirrhosis
|
COPD/CHF/Cirrhosis
| 3
| 10
|
under $11k
| 9
| 3,491
| null | null | 8
|
black
| 26.5
| 35
| 0.810913
| 0.69397
| 1
| 0
| 0
|
no
| 0.5
| 0.3
|
no dnr
| 4
| 58
| 21.699219
| 115
| 10
| 38.59375
| 150
| null | null | 2.199707
| 139
| 7.489258
| 156
| 54
| 1,315
| null | null |
no(M2 and SIP pres)
| 2.38916
| 439
| 0
|
46.58698
|
female
| 0
| 45
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 18
|
>$50k
| 37
| 125,548
| null | null | 32.75
|
black
| 23.796875
| 40
| 0.75
| 0.671997
| 3
| 1
| 0
|
no
| 0.75
| 0.75
|
no dnr
| 45
| 113
| null | 55
| 30
| 36.5
| null | null | null | null | 140
| null | 420
| null | 4,005
| null | 0
|
adl>=4 (>=5 if sur)
| 0
| 365
| 1
|
50.57098
|
female
| 1
| 7
|
Cirrhosis
|
COPD/CHF/Cirrhosis
| 2
| 12
|
under $11k
| 0
| 42,242
| null | null | 18
|
black
| 21
| 25
| 0.825928
| 0.715942
| 1
| 0
| 0
|
no
| null | null |
dnr after sadm
| 7
| 155
| 6.799805
| 105
| 30
| 36.39844
| 144.4375
| null | null | 1.299805
| 137
| 7.509766
| 267
| 26
| 1,460
| 4
| 4
|
<2 mo. follow-up
| 4
| 7
| 1
|
74.85797
|
female
| 0
| 41
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| null |
under $11k
| 44
| 51,726
| null | null | 20
|
white
| 23.796875
| 40
| 0.620972
| 0.515991
| 1
| 0
| 0
|
no
| 0.5
| 0.3
|
dnr after sadm
| 7
| 58
| 19.699219
| 115
| 56
| 38.59375
| 200
| 3.099609
| 36.195313
| 4.199219
| 137
| 7.40918
| 122
| 136
| 665
| null | 0
|
<2 mo. follow-up
| 0
| 52
| 1
|
68.71698
|
male
| 1
| 21
|
MOSF w/Malig
|
ARF/MOSF
| 1
| 7
| null | 0
| 84,442
| null | null | 29.333328
|
white
| 28.097656
| 35
| 0.599976
| 0.492981
| 1
| 0
| 0
|
yes
| 0.1
| 0.05
|
dnr after sadm
| 14
| 79
| 10.099609
| 68
| 20
| 37.69531
| null | 4
| 0.599976
| 0.899902
| 138
| null | 86
| 7
| 4,970
| null | 1
|
<2 mo. follow-up
| 1
| 21
| 1
|
66.54596
|
male
| 0
| 40
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 12
|
$11-$25k
| 0
| 162,193
| null | null | 34.75
|
white
| 21.398438
| 26
| 0.796997
| 0.72998
| 7
| 0
| 0
|
no
| null | null |
no dnr
| 40
| 115
| 13.699219
| 135
| 32
| 38.59375
| 185.6875
| null | null | 0.599976
| 136
| 7.479492
| 185
| 9
| 950
| null | 0
|
no(M2 and SIP pres)
| 0
| 165
| 1
|
63.75098
|
female
| 0
| 33
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 16
| null | 0
| 106,855
| null | null | 28.75
|
white
| 23.398438
| 44
| 0.647949
| 0.547974
| 11
| 0
| 0
|
metastatic
| 0.7
| 0.5
|
no dnr
| 33
| 72
| 33.5
| 65
| 32
| 37.69531
| 116.3125
| 3
| 2.099609
| 0.899902
| 131
| 7.399414
| 98
| 15
| 3,475
| null | 1
|
adl>=4 (>=5 if sur)
| 1
| 437
| 0
|
57.487
|
male
| 1
| 7
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 13
| null | 0
| 78,351
| null | null | 32
|
white
| 37.398438
| 57
| 0.533936
| 0.418945
| 3
| 0
| 0
|
no
| null | null |
dnr after sadm
| 3
| 103
| 5.699219
| 64
| 28
| 36.5
| 340
| null | 0.5
| 0.699951
| 137
| 7.40918
| 133
| 14
| 550
| null | 0
|
<2 mo. follow-up
| 0
| 7
| 1
|
72.73596
|
female
| 0
| 40
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 11
|
under $11k
| 26
| 145,725
| null | null | 31.25
|
black
| 26.5
| 65
| 0.602905
| 0.495972
| 3
| 0
| 0
|
no
| null | null |
no dnr
| 40
| 60
| 15.5
| 105
| 24
| 38.89844
| 170
| 2.599609
| 0.5
| 4.899414
| 141
| 7.389648
| 232
| 61
| 3,765
| null | 2
|
no(M2 and SIP pres)
| 2
| 436
| 0
|
57.29199
|
male
| 0
| 31
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 14
|
>$50k
| 0
| 121,247
| null | null | 22.5
|
white
| 26.699219
| 41
| 0.750977
| 0.671997
| 6
| 0
| 0
|
no
| 0.8
| 0.8
|
no dnr
| 31
| 122
| 0.099991
| 115
| 42
| 38.79688
| 135
| null | 1.699951
| 0.5
| 136
| 7.439453
| 232
| 12
| 5,620
| null | 0
|
adl>=4 (>=5 if sur)
| 0
| 435
| 0
|
70.73499
|
male
| 1
| 4
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| null | null | 100
| 20,379
| null | null | 34
|
white
| 41
| 71
| 0.018997
| 0.004
| 1
| 0
| 0
|
no
| 0.1
| 0.05
|
dnr after sadm
| 3
| 75
| 5.299805
| 72
| 24
| 36.39844
| null | 2.5
| 5.799805
| 1
| 134
| null | 112
| 31
| 925
| null | null |
<2 mo. follow-up
| 3.334473
| 4
| 1
|
64.43799
|
male
| 0
| 52
|
CHF
|
COPD/CHF/Cirrhosis
| 2
| null | null | 0
| 165,091
| null | null | 13.75
|
white
| 12.199219
| 20
| 0.924927
| 0.871948
| 1
| 0
| 0
|
no
| null | null |
no dnr
| 52
| 107
| 10.798828
| 45
| 34
| 35.19531
| 115.29688
| null | null | 0.5
| 133
| 7.339844
| 131
| 20
| 1,730
| null | null | null | 2.231934
| 434
| 0
|
72.85699
|
male
| 0
| 14
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 4
| 10
|
under $11k
| 9
| 35,895
| null | null | 22
|
black
| 21.699219
| 37
| 0.740967
| 0.659912
| 1
| 1
| 0
|
yes
| 0.7
| 0.5
|
no dnr
| 14
| 81
| 8.599609
| 68
| 20
| 37.79688
| null | null | 0.599976
| 0.699951
| 138
| null | 116
| 4
| null | 1
| null | null | 1.166748
| 225
| 1
|
77.35797
|
female
| 0
| 10
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| null | null | 9
| 87,387
| null | null | 27.5
|
white
| 18.597656
| 19
| 0.75293
| 0.674927
| 21
| 1
| 0
|
no
| null | null |
no dnr
| 10
| 122
| null | 140
| 12
| 36
| 205
| null | null | 1.199951
| 141
| 7.519531
| 103
| 32
| 165.5
| null | null | null | 2.695313
| 433
| 0
|
69.76599
|
female
| 0
| 3
|
Colon Cancer
|
Cancer
| 2
| 12
|
under $11k
| 0
| 11,018
| null | null | 9
|
white
| 17.199219
| 23
| 0.804932
| 0.583984
| 1
| 0
| 0
|
metastatic
| null | null |
no dnr
| 3
| 42
| 30.097656
| 155
| 8
| 35.89844
| 256.625
| 1.199951
| 2.5
| 4
| 133
| 7.279297
| 109
| 136
| 712
| null | null |
SIP>=30
| 1.869629
| 101
| 1
|
69.40497
|
male
| 0
| 13
|
COPD
|
COPD/CHF/Cirrhosis
| 4
| 12
|
under $11k
| 0
| 28,535
| null | null | 23
|
white
| 26.597656
| 24
| 0.748901
| 0.603882
| 1
| 0
| 0
|
no
| 0.95
| 0.95
|
no dnr
| 13
| 75
| 11.398438
| 155
| 34
| 38.29688
| 240
| 1.199951
| null | 1.799805
| 142
| 7.459961
| 229
| 48
| 3,990
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 388
| 1
|
49.45697
|
male
| 0
| 15
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 12
|
under $11k
| 44
| null | null | null | 24
|
white
| 18.699219
| 41
| 0.762939
| 0.687988
| 17
| 0
| 0
|
no
| 0.6
| 0.5
| null | null | 72
| 19
| 45
| 34
| 38.09375
| 233.3125
| 2.799805
| 0.699951
| 0.699951
| 136
| 7.449219
| 94
| 39
| 1,375
| null | 0
|
adl>=4 (>=5 if sur)
| 0
| 83
| 1
|
51.82199
|
male
| 0
| 16
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 8
|
under $11k
| 0
| 75,528
| null | null | 17
|
white
| 29.296875
| 36
| 0.738892
| 0.657959
| 4
| 0
| 0
|
no
| 0.6
| 0.5
|
no dnr
| 16
| 132
| 12.199219
| 125
| 32
| 36.19531
| 215
| 2.699707
| 4.399414
| 2.799805
| 145
| 7.479492
| 79
| 100
| 2,325
| null | 0
|
SIP>=30
| 0
| 432
| 0
|
82.65594
|
female
| 0
| 8
|
CHF
|
COPD/CHF/Cirrhosis
| 2
| 7
| null | 26
| 17,117
| null | null | 15.5
|
white
| 28.296875
| 30
| 0.533936
| 0.334961
| 1
| 0
| 0
|
no
| 0.7
| 0.5
|
dnr before sadm
| -1
| 73
| 7.799805
| 105
| 22
| 35.79688
| 200
| null | null | 1.099854
| 141
| 7.369141
| 96
| 20
| 2,300
| 0
| 0
|
<2 mo. follow-up
| 0
| 53
| 1
|
50.06198
|
female
| 1
| 8
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 12
|
under $11k
| 0
| 50,018
| null | null | 48
|
white
| 41.195313
| 106
| 0.522949
| 0.407959
| 1
| 0
| 0
|
no
| 0.3
| 0.15
|
dnr after sadm
| 3
| 72
| 6.199219
| 119
| 32
| 35.5
| 293.3125
| null | null | 1.099854
| 138
| 7.389648
| 69
| 29
| 2,525
| null | 0
|
<2 mo. follow-up
| 0
| 8
| 1
|
61.26199
|
male
| 0
| 18
|
Colon Cancer
|
Cancer
| 2
| 8
|
$25-$50k
| 0
| 37,422
| null | null | 18.666656
|
white
| 35.09375
| 27
| 0.429993
| 0.122986
| 1
| 1
| 0
|
metastatic
| null | null |
no dnr
| 18
| 48
| 13.699219
| 135
| 47
| 39.09375
| 148
| null | 0.599976
| 1.699951
| 147
| 7.389648
| 211
| 21
| 1,945
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 431
| 0
|
50.20898
|
male
| 0
| 10
|
Colon Cancer
|
Cancer
| 1
| 14
|
$25-$50k
| 0
| 14,872
| null | null | 11.5
|
white
| 15.099609
| 6
| 0.863892
| 0.694946
| 1
| 0
| 0
|
metastatic
| 0.9
| 0.7
|
no dnr
| 10
| 38
| 18.097656
| 115
| 27
| 39
| 100
| 2
| 4.099609
| 2.5
| 148
| 7.349609
| 162
| 71
| 2,040
| 1
| 1
|
no(M2 and SIP pres)
| 1
| 430
| 0
|
45.76599
|
male
| 0
| 4
|
Lung Cancer
|
Cancer
| 2
| 12
| null | 0
| 5,333
| null | null | 13
|
white
| 43.195313
| 54
| 0.088989
| 0.003
| 1
| 1
| 0
|
metastatic
| 0.4
| 0.1
|
dnr after sadm
| 2
| 72
| 10.398438
| 75
| 8
| 39
| 120
| 2
| 0.699951
| 1.099854
| 140
| 7.399414
| 68
| 17
| 1,770
| 3
| 4
|
<2 mo. follow-up
| 4
| 38
| 1
|
70.34595
|
male
| 0
| 14
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 12
|
$11-$25k
| 9
| 22,967
| null | null | 14.333328
|
white
| 24.5
| 45
| 0.754883
| 0.677979
| 1
| 0
| 0
|
no
| 0.75
| 0.75
|
no dnr
| 14
| 68
| 15.298828
| 115
| 30
| 38.39844
| 226.65625
| 1.799805
| 1.099854
| 6.799805
| 141
| 7.349609
| 77
| 71
| 5
| null | 0
|
no(M2 and SIP pres)
| 0
| 428
| 0
|
60.47897
|
female
| 0
| 9
|
COPD
|
COPD/CHF/Cirrhosis
| 2
| 8
|
under $11k
| 0
| 11,988
| null | null | 13
|
white
| 22.398438
| 34
| 0.859985
| 0.768921
| 1
| 0
| 0
|
no
| 0.95
| 0.95
|
no dnr
| 9
| 55
| 5.799805
| 70
| 36
| 35.79688
| 203.3125
| 1.5
| 0.5
| 2.5
| 133
| 7.359375
| 139
| 50
| 2,760
| 2
| 0
|
SIP>=30
| 0
| 428
| 0
|
75.29395
|
male
| 1
| 4
|
MOSF w/Malig
|
ARF/MOSF
| 1
| 16
|
>$50k
| 44
| 23,497
| null | null | 37
|
white
| 31.699219
| 43
| 0.133972
| 0.060997
| 4
| 0
| 0
|
metastatic
| 0.1
| 0
|
dnr after sadm
| 2
| 152
| 5.5
| 60
| 30
| 38.69531
| 228.5625
| null | null | 0.899902
| 134
| 7.439453
| 103
| 13
| 1,320
| null | 0
|
<2 mo. follow-up
| 0
| 4
| 1
|
65.396
|
male
| 0
| 25
|
COPD
|
COPD/CHF/Cirrhosis
| 5
| null | null | 9
| 78,471
| null | null | 26.25
|
white
| 31
| 34
| 0.662964
| 0.487976
| 1
| 1
| 0
|
no
| 0.7
| 0.6
|
dnr after sadm
| 16
| 108
| 9.699219
| 160
| 35
| 37.79688
| 165
| null | null | 0.699951
| 137
| 7.479492
| 130
| 17
| 3,775
| null | null |
<2 mo. follow-up
| 3.592773
| 38
| 1
|
69.08698
|
male
| 0
| 8
|
Lung Cancer
|
Cancer
| 1
| 14
| null | 0
| 13,090
| null | null | 13
|
white
| 16.097656
| 6
| 0.715942
| 0.436951
| 1
| 0
| 0
|
metastatic
| 0.7
| 0.3
|
no dnr
| 8
| 61
| 5
| 76
| 24
| 36.79688
| null | 2.5
| 1.699951
| 3
| 136
| null | 120
| 56
| 1,275
| 0
| null | null | 0.494751
| 225
| 1
|
59.61398
|
female
| 0
| 8
|
Colon Cancer
|
Cancer
| 1
| 15
|
>$50k
| 0
| 17,474
| null | null | 10
|
white
| 3
| 16
| 0.940918
| 0.859985
| 1
| 0
| 0
|
metastatic
| 0.9
| 0.8
|
no dnr
| 8
| 67
| 15.398438
| 105
| 28
| 35.89844
| 170
| 3.299805
| null | 4.599609
| 127
| 7.349609
| 200
| 101
| 3,355
| 0
| null | null | 0.494751
| 173
| 1
|
51.06897
|
male
| 0
| 50
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 16
|
under $11k
| 0
| 153,904
| null | null | 33.25
|
hispanic
| 30
| 19
| 0.766968
| 0.692993
| 1
| 0
| 0
|
no
| 0.8
| 0.7
|
no dnr
| 50
| 112
| 15.5
| 115
| 50
| 39.09375
| 191.40625
| null | 0.899902
| 0.799927
| 141
| 7.449219
| 103
| 11
| 4,955
| null | null |
no(M2 and SIP pres)
| 2.137207
| 424
| 0
|
55.36798
|
male
| 0
| 12
|
Cirrhosis
|
COPD/CHF/Cirrhosis
| 1
| 1
|
under $11k
| 0
| 41,291
| null | null | 37
|
white
| 22.199219
| 29
| 0.783936
| 0.653931
| 1
| 0
| 0
|
no
| 0.6
| 0.6
|
no dnr
| 12
| 138
| 10
| 135
| 25
| 37.79688
| 167.5
| null | null | 6
| 136
| 7.399414
| 101
| 58
| 0
| null | 1
|
no(M2 and SIP pres)
| 1
| 226
| 1
|
68.646
|
female
| 0
| 8
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 12
|
$11-$25k
| 0
| 14,600
| null | null | 6
|
white
| 19.796875
| 25
| 0.837891
| 0.782959
| 2
| 0
| 0
|
no
| 0.8
| 0.8
|
no dnr
| 8
| 67
| 9.298828
| 70
| 20
| 36.5
| null | 2.099609
| 1.399902
| 1.299805
| 132
| null | 59
| 40
| 4,450
| 1
| null |
no(M2 and SIP pres)
| 1.166748
| 423
| 0
|
72.71198
|
male
| 0
| 7
|
CHF
|
COPD/CHF/Cirrhosis
| 3
| 12
|
>$50k
| 0
| 10,007
| null | null | 9.5
|
white
| 23
| 36
| 0.797974
| 0.674927
| 1
| 0
| 0
|
no
| 0.95
| 0.75
|
no dnr
| 7
| 73
| 5.699219
| 96
| 20
| 36.29688
| null | 3.899902
| 0.5
| 0.799927
| 137
| null | 90
| 5
| 5,175
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 424
| 0
|
67.50397
|
male
| 0
| 49
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 12
| null | 37
| 162,444
| null | null | 26
|
white
| 27.296875
| 61
| 0.5
| 0.381958
| 16
| 0
| 0
|
no
| 0.5
| 0.45
|
no dnr
| 49
| 79
| 5.799805
| 64
| 16
| 37
| null | 3.599609
| 0.799927
| 0.899902
| 137
| null | 90
| 11
| 4,725
| null | 0
|
SIP>=30
| 0
| 422
| 0
|
74.81696
|
male
| 1
| 6
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 10
| null | 44
| 22,608
| null | null | 31
|
white
| 22.699219
| 32
| 0.644897
| 0.543945
| 1
| 0
| 0
|
no
| null | null |
dnr after sadm
| 2
| 73
| 12.099609
| 119
| 22
| 35.79688
| 476
| null | null | 0.799927
| 132
| 7.479492
| 208
| 11
| 3,520
| null | null |
<2 mo. follow-up
| 2.480957
| 6
| 1
|
74.93195
|
male
| 1
| 42
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 11
|
$11-$25k
| 9
| null | null | null | 24
|
white
| 43.09375
| 46
| 0.247986
| 0.144989
| 1
| 0
| 0
|
no
| 0.4
| 0.2
| null | null | 77
| 5.799805
| 66
| 24
| 36.39844
| null | null | 2
| 1.699951
| 132
| null | 88
| 34
| 1,200
| null | 7
|
<2 mo. follow-up
| 7
| 42
| 1
|
40.24899
|
female
| 0
| 49
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 12
|
$11-$25k
| 26
| 211,918
| null | null | 42.5
|
white
| 34.796875
| 69
| 0.629883
| 0.527954
| 1
| 0
| 0
|
no
| 0.4
| 0.3
|
no dnr
| 49
| 113
| 3.199707
| 72
| 22
| 37.69531
| null | 3.899902
| 1.299805
| 1.199951
| 136
| null | 112
| 13
| 3,600
| null | 0
|
no(M2 and SIP pres)
| 0
| 422
| 0
|
70.89697
|
male
| 1
| 20
|
Lung Cancer
|
Cancer
| 4
| 13
| null | 0
| 28,242
| null | null | 14.666664
|
white
| 30.597656
| 30
| 0.330994
| 0.064987
| 1
| 1
| 0
|
metastatic
| 0.4
| 0.4
|
dnr after sadm
| 12
| 108
| 14.5
| 104
| 32
| 35.79688
| 242.84375
| null | 1.299805
| 1
| 139
| 7.479492
| 112
| 37
| 3,900
| null | 0
|
<2 mo. follow-up
| 0
| 20
| 1
|
34.60098
|
female
| 0
| 56
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 12
| null | 0
| 227,914
| null | null | 41
|
black
| 27.699219
| 38
| 0.851929
| 0.800903
| 1
| 0
| 0
|
no
| 0.8
| 0.8
|
no dnr
| 56
| 62
| 8.298828
| 125
| 44
| 36.69531
| 280
| 2.599609
| 1.5
| 1.299805
| 138
| 7.419922
| 108
| 28
| 2,315
| null | 0
|
no(M2 and SIP pres)
| 0
| 421
| 0
|
81.71899
|
female
| 1
| 7
|
Coma
|
Coma
| 2
| null |
under $11k
| 44
| 26,992
| null | null | 30
|
black
| 23.5
| 30
| 0.250977
| 0.18399
| 1
| 1
| 0
|
yes
| 0.5
| 0.5
|
dnr after sadm
| 4
| 113
| 43.398438
| 125
| 29
| 38
| 187.5
| 2.5
| 1.399902
| 6.699219
| 139
| 7.329102
| 112
| 87
| 2,055
| null | 3
|
<2 mo. follow-up
| 3
| 7
| 1
|
66.43695
|
male
| 0
| 6
|
Lung Cancer
|
Cancer
| 2
| null | null | 0
| 12,589
| null | null | 15
|
white
| 14.099609
| 10
| 0.758911
| 0.504883
| 1
| 0
| 0
|
metastatic
| 0.7
| 0.5
|
no dnr
| 6
| 65
| 16.597656
| 105
| 36
| 38.89844
| 306.625
| 2
| null | 1.899902
| 160
| 7.459961
| 129
| 35
| 1,365
| null | null | null | 2.085938
| 180
| 1
|
55.754
|
male
| 0
| 24
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 18
|
>$50k
| 37
| 75,213
| null | null | 28.333328
|
white
| 33.59375
| 95
| 0.468994
| 0.349976
| 3
| 0
| 0
|
no
| 0.9
| 0.9
|
no dnr
| 24
| 57
| 6.099609
| 110
| 9
| 37.59375
| 175.5
| null | null | 0.899902
| 135
| 7.449219
| 142
| 16
| 2,645
| null | 0
|
no(M2 and SIP pres)
| 0
| 420
| 0
|
65.55194
|
male
| 0
| 32
|
Coma
|
Coma
| 1
| 12
| null | 94
| 65,156
| null | null | 25
|
white
| 21.699219
| 25
| 0.294983
| 0.224976
| 1
| 0
| 0
|
no
| 0.5
| 0.5
|
dnr after sadm
| 4
| 78
| 8.898438
| 118
| 34
| 36.89844
| null | 2.799805
| 0.799927
| 0.799927
| 139
| null | 91
| 4
| 2,700
| null | 0
| null | 0
| 63
| 1
|
68.84094
|
female
| 0
| 12
|
COPD
|
COPD/CHF/Cirrhosis
| 1
| null | null | 0
| 13,711
| null | null | 6.5
|
white
| 25.199219
| 26
| 0.775879
| 0.642944
| 1
| 0
| 0
|
no
| null | null |
dnr after sadm
| 1
| 72
| 5.5
| 115
| 14
| 37.09375
| 210
| 3.299805
| 0.699951
| 0.599976
| 136
| 7.379883
| 96
| 3
| 3,905
| null | null |
<2 mo. follow-up
| 3.021484
| 32
| 1
|
86.17395
|
male
| 1
| 4
|
Coma
|
Coma
| 0
| null | null | 100
| 7,012
| null | null | 8
|
white
| 19.296875
| 31
| 0.139984
| 0.089996
| 1
| 0
| 0
|
no
| null | null |
dnr after sadm
| 1
| 118
| 20.5
| 53
| 36
| 38.19531
| 236.65625
| 2.099609
| 0.399963
| 1
| 134
| 7.449219
| 92
| 31
| 1,540
| null | null |
<2 mo. follow-up
| 2.823731
| 4
| 1
|
50.61697
|
male
| 1
| 4
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| null | null | 26
| 82,086
| null | null | 40
|
black
| 42.898438
| 80
| 0.212982
| 0.117996
| 22
| 0
| 0
|
no
| null | null |
dnr after sadm
| 4
| 115
| 17.199219
| 115
| 7
| 37.79688
| 213.3125
| 2
| 0.299988
| 1
| 133
| 7.439453
| 243
| 22
| 3,590
| null | null |
<2 mo. follow-up
| 2.580078
| 4
| 1
|
48.73099
|
female
| 0
| 11
|
Lung Cancer
|
Cancer
| 1
| 12
| null | 0
| 15,076
| null | null | 10.5
|
white
| 5.399414
| 12
| 0.890991
| 0.751953
| 1
| 0
| 0
|
metastatic
| 0.75
| 0.5
|
no dnr
| 11
| 79
| 4.099609
| 75
| 20
| 36.69531
| null | null | 0.599976
| 0.799927
| 139
| null | 212
| 8
| 1,100
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 418
| 0
|
60.92499
|
female
| 0
| 44
|
Coma
|
Coma
| 0
| 12
|
under $11k
| 61
| 115,272
| null | null | 31.5
|
black
| 18.597656
| 28
| 0.553955
| 0.484985
| 3
| 0
| 0
|
no
| 0.05
| 0.05
|
no dnr
| 44
| 65
| 9.599609
| 72
| 12
| 36.19531
| null | 2.699707
| 17.597656
| 0.699951
| 136
| null | 95
| 11
| null | null | 0
|
adl>=4 (>=5 if sur)
| 0
| 418
| 0
|
80.51495
|
male
| 1
| 6
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 8
|
under $11k
| 9
| 57,044
| null | null | 41
|
white
| 23.796875
| 45
| 0.657959
| 0.559937
| 8
| 1
| 0
|
no
| 0.3
| 0.2
|
dnr after sadm
| 2
| 125
| 6.899414
| 170
| 8
| 40.29688
| 438.0625
| null | null | 0.599976
| 134
| 7.479492
| 377
| 8
| 2,820
| null | 0
|
<2 mo. follow-up
| 0
| 6
| 1
|
49.54398
|
female
| 0
| 6
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 11
| null | 9
| 19,758
| null | null | 23
|
black
| 21
| 14
| 0.85791
| 0.80896
| 2
| 0
| 0
|
no
| 0.8
| 0.75
|
no dnr
| 6
| 75
| 8.298828
| 68
| 20
| 37
| null | 2
| 4.899414
| 0.899902
| 129
| null | 112
| 12
| null | 0
| 0
|
SIP>=30
| 0
| 417
| 0
|
68.44098
|
male
| 1
| 4
|
MOSF w/Malig
|
ARF/MOSF
| 2
| 17
|
>$50k
| 44
| 22,156
| null | null | 46
|
white
| 28
| 40
| 0.322998
| 0.208984
| 4
| 0
| 0
|
yes
| 0.05
| 0.05
|
dnr after sadm
| 2
| 73
| 18.898438
| 78
| 12
| 36.59375
| 276.625
| null | 1
| 6.799805
| 131
| 7.459961
| 139
| 107
| 1,005
| null | 7
|
<2 mo. follow-up
| 7
| 4
| 1
|
65.47797
|
male
| 1
| 4
|
COPD
|
COPD/CHF/Cirrhosis
| 2
| 12
|
$11-$25k
| 0
| 4,656
| null | null | 9
|
white
| 29.398438
| 32
| 0.668945
| 0.495972
| 1
| 0
| 0
|
yes
| 0.6
| 0.4
|
no dnr
| 4
| 70
| 8.798828
| 110
| 16
| 36.39844
| 217.5
| 2.899902
| null | 4.5
| 130
| 7.419922
| 74
| 113
| 2,510
| 6
| 4
|
<2 mo. follow-up
| 4
| 4
| 1
|
73.04297
|
female
| 0
| 12
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 6
|
under $11k
| 0
| 29,016
| null | null | 25.5
|
black
| 24.398438
| 59
| 0.772949
| 0.699951
| 1
| 1
| 0
|
no
| 0.2
| 0.2
|
no dnr
| 12
| 142
| 5.799805
| 115
| 28
| 38.59375
| 227.5
| 2.699707
| null | 0.699951
| 138
| 7.429688
| 121
| 18
| 2,360
| null | 0
|
adl>=4 (>=5 if sur)
| 0
| 263
| 1
|
77.08698
|
male
| 0
| 19
|
CHF
|
COPD/CHF/Cirrhosis
| 2
| null | null | 0
| 39,533
| null | null | 26.333328
|
white
| 25.5
| 32
| 0.737915
| 0.588989
| 1
| 0
| 0
|
no
| null | null |
no dnr
| 19
| 60
| 10.699219
| 115
| 5
| 36.79688
| 251.40625
| 1
| null | 1.099854
| 136
| 7.369141
| 141
| 7
| 3,352
| null | null | null | 2.953613
| 65
| 1
|
45.64499
|
male
| 0
| 7
|
Lung Cancer
|
Cancer
| 1
| 23
|
$25-$50k
| 0
| 7,302
| null | null | 6.5
|
white
| 21.097656
| 10
| 0.669922
| 0.370972
| 1
| 0
| 0
|
metastatic
| 0.6
| 0.3
|
no dnr
| 7
| 48
| 22.398438
| 175
| 28
| 39.89844
| 130
| null | null | 0.899902
| 142
| 7.359375
| 178
| 18
| 1,710
| 0
| null |
no(M2 and SIP pres)
| 0.494751
| 415
| 0
|
50.02597
|
male
| 0
| 20
|
MOSF w/Malig
|
ARF/MOSF
| 1
| 12
|
$11-$25k
| 41
| 66,125
| null | null | 22
|
white
| 33.796875
| 70
| 0.185974
| 0.096985
| 1
| 0
| 0
|
metastatic
| null | null |
no dnr
| 20
| 108
| 15
| 70
| 4
| 36.09375
| 320
| null | null | 7.5
| 137
| 7.399414
| 121
| 47
| 0
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 415
| 0
|
78.72095
|
male
| 1
| 31
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 1
| 7
|
$11-$25k
| 41
| 112,577
| null | null | 32.75
|
black
| 34
| 56
| 0.237
| 0.135986
| 1
| 0
| 0
|
yes
| 0.2
| 0.1
|
dnr after sadm
| 4
| 105
| 13.298828
| 120
| 13
| 39.29688
| 193.3125
| 2.399902
| 1.799805
| 0.799927
| 133
| 7.449219
| 105
| 20
| 3,700
| null | 0
|
<2 mo. follow-up
| 0
| 31
| 1
|
55.38898
|
male
| 1
| 79
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 2
| 7
|
$11-$25k
| 0
| 292,373
| null | null | 41.75
|
white
| 31.5
| 57
| 0.669922
| 0.573975
| 5
| 0
| 0
|
no
| null | null |
dnr after sadm
| 17
| 49
| 5.5
| 0
| 0
| 39.29688
| 177
| 2.899902
| 0.5
| 1.199951
| 147
| 7.549805
| 312
| 28
| 4,065
| null | 0
|
adl>=4 (>=5 if sur)
| 0
| 79
| 1
|
63.24399
|
female
| 0
| 11
|
Coma
|
Coma
| 2
| 10
| null | 0
| 13,705
| null | null | 13
|
white
| 23.199219
| 27
| 0.651978
| 0.592896
| 1
| 0
| 0
|
yes
| 0.2
| 0.05
|
dnr before sadm
| -1
| 77
| 15.099609
| 84
| 20
| 36.09375
| null | 4.299805
| 0.699951
| 1.299805
| 142
| null | 92
| 26
| 1,125
| null | 1
|
adl>=4 (>=5 if sur)
| 1
| 66
| 1
|
95.53699
|
male
| 1
| 4
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| null | null | 61
| 11,729
| null | null | 26
|
white
| 35.796875
| 66
| 0.088989
| 0.034996
| 1
| 0
| 0
|
no
| 0.5
| 0.5
|
no dnr
| 4
| 107
| 71.6875
| 45
| 13
| 36.59375
| 251.84375
| 3.399902
| 0.599976
| 1.199951
| 138
| 7.40918
| 79
| 23
| 2,470
| null | 0
|
<2 mo. follow-up
| 0
| 4
| 1
|
27.25299
|
female
| 0
| 38
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 12
|
$11-$25k
| 37
| 161,518
| null | null | 37
|
white
| 31.898438
| 47
| 0.652954
| 0.553955
| 7
| 0
| 0
|
no
| 0.6
| 0.2
|
no dnr
| 38
| 115
| 14
| 105
| 24
| 37.79688
| 340
| 2.699707
| null | 0.799927
| 136
| 7.469727
| 189
| 25
| 1,935
| null | 0
|
no(M2 and SIP pres)
| 0
| 412
| 0
|
53.728
|
male
| 1
| 7
|
MOSF w/Malig
|
ARF/MOSF
| 1
| 11
|
under $11k
| 37
| 33,447
| null | null | 36
|
black
| 27.699219
| 62
| 0.30896
| 0.196991
| 4
| 0
| 0
|
metastatic
| 0.3
| 0.15
|
dnr after sadm
| 2
| 103
| 8.699219
| 55
| 12
| 36.59375
| null | null | 0.299988
| 0.899902
| 141
| null | 128
| 14
| 850
| null | 1
|
<2 mo. follow-up
| 1
| 7
| 1
|
50.73199
|
male
| 0
| 4
|
Lung Cancer
|
Cancer
| 1
| 14
|
$25-$50k
| 0
| 5,207
| null | null | 11
|
white
| 18.296875
| 20
| 0.715942
| 0.436951
| 1
| 0
| 0
|
metastatic
| 0.75
| 0.6
|
no dnr
| 4
| 115
| 8.199219
| 115
| 12
| 36.79688
| 142.5
| 3.299805
| null | 1.099854
| 135
| 7.359375
| 111
| 18
| 2,080
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 185
| 1
|
44.89798
|
male
| 0
| 12
|
Colon Cancer
|
Cancer
| 1
| 12
| null | 0
| 33,648
| null | null | 24
|
black
| 49.796875
| 36
| 0.097992
| 0.003
| 1
| 0
| 0
|
metastatic
| null | null |
no dnr
| 12
| 108
| 17.5
| 60
| 32
| 36.29688
| 286.625
| 1.899902
| 0.599976
| 1
| 140
| 7.459961
| 120
| 21
| 1,180
| 0
| 0
|
no(M2 and SIP pres)
| 0
| 411
| 0
|
39.90997
|
male
| 0
| 6
|
Colon Cancer
|
Cancer
| 1
| 12
|
$11-$25k
| 0
| 8,356
| null | null | 12
|
black
| 6.099609
| 10
| 0.938965
| 0.85498
| 1
| 0
| 0
|
metastatic
| 0.8
| 0.6
|
no dnr
| 6
| 127
| 5.899414
| 120
| 10
| 38.5
| 157.5
| 1.899902
| 1.5
| 0.699951
| 127
| 7.459961
| 99
| 10
| 5,565
| 0
| null |
no(M2 and SIP pres)
| 0.494751
| 411
| 0
|
66.80896
|
male
| 1
| 11
|
Lung Cancer
|
Cancer
| 2
| 12
|
under $11k
| 9
| 9,857
| null | null | 11.5
|
white
| 24.398438
| 47
| 0.483948
| 0.164978
| 1
| 1
| 0
|
metastatic
| 0.2
| 0.05
|
dnr after sadm
| 3
| 72
| 6.799805
| 75
| 32
| 35.29688
| 287.75
| 2.699707
| 0.399963
| 1.299805
| 126
| 7.419922
| 96
| 49
| 2,555
| null | 0
|
<2 mo. follow-up
| 0
| 11
| 1
|
40.129
|
male
| 1
| 14
|
ARF/MOSF w/Sepsis
|
ARF/MOSF
| 0
| 12
| null | 0
| 98,253
| null | null | 45
|
black
| 41.5
| 71
| 0.552979
| 0.439941
| 2
| 0
| 0
|
no
| 0.5
| 0.5
|
dnr after sadm
| 14
| 42
| 22
| 155
| 37
| 34.69531
| 234.28125
| 1.399902
| 1.699951
| 1.399902
| 144
| 7.199219
| 57
| 27
| 1,260
| null | 0
|
<2 mo. follow-up
| 0
| 14
| 1
|
40.24899
|
male
| 0
| 6
|
Colon Cancer
|
Cancer
| 1
| 16
|
>$50k
| 0
| 11,127
| null | null | 14
|
white
| 11
| 6
| 0.909912
| 0.791992
| 1
| 0
| 0
|
metastatic
| 0.9
| 0.8
|
no dnr
| 6
| 130
| 6.399414
| 75
| 8
| 35
| 428.5625
| 2.099609
| 0.799927
| 0.699951
| 134
| 7.469727
| 244
| 7
| null | 0
| null | null | 0.494751
| 410
| 0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.